Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Average Price Target from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $7.00.

Several equities research analysts have issued reports on the stock. JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reissued a "buy" rating and issued a $6.00 price objective (up previously from $4.00) on shares of Precigen in a research note on Thursday, January 23rd.

Precigen Trading Down 3.0 %

Shares of PGEN traded down $0.06 during trading hours on Friday, reaching $1.97. 1,670,334 shares of the company traded hands, compared to its average volume of 2,177,640. The stock's fifty day moving average price is $1.23 and its 200 day moving average price is $1.05. The firm has a market cap of $576.95 million, a price-to-earnings ratio of -3.58 and a beta of 1.66. Precigen has a 12-month low of $0.65 and a 12-month high of $2.17.

Institutional Investors Weigh In On Precigen

Several hedge funds have recently modified their holdings of PGEN. BNP Paribas Financial Markets bought a new position in Precigen in the fourth quarter worth about $27,000. Traphagen Investment Advisors LLC acquired a new stake in Precigen in the third quarter valued at approximately $29,000. Stifel Financial Corp grew its holdings in Precigen by 94.9% in the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 15,680 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Precigen by 29.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 5,915 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Precigen during the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 33.51% of the company's stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.